{
  "_metadata": {
    "title": "Clinical Phase Transition Probabilities and Trial Costs Reference Data",
    "description": "Comprehensive reference data for biotech DCF valuations including phase transition success rates and clinical trial costs by therapeutic area and indication",
    "last_updated": "2026-01-19",
    "sources": {
      "BIO_QLS_2021": {
        "title": "Clinical Development Success Rates and Contributing Factors 2011-2020",
        "authors": "BIO, Informa Pharma Intelligence, QLS Advisors",
        "year": 2021,
        "url": "https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf",
        "notes": "Analysis of 12,728 clinical phase transitions from 9,704 drug development programs across 1,779 companies (Jan 2011 - Nov 2020). Primary source for success rates."
      },
      "Wong_2019": {
        "title": "Estimation of clinical trial success rates and related parameters",
        "authors": "Wong CH, Siah KW, Lo AW",
        "journal": "Biostatistics",
        "year": 2019,
        "url": "https://doi.org/10.1093/biostatistics/kxx069",
        "notes": "Analysis of 406,038 clinical trial entries from 2000-2015. Used for biomarker phase-specific multipliers."
      },
      "ASPE_2014": {
        "title": "Examination of Clinical Trial Costs and Barriers for Drug Development",
        "authors": "Eastern Research Group for ASPE/HHS",
        "year": 2014,
        "url": "https://aspe.hhs.gov/reports/examination-clinical-trial-costs-barriers-drug-development-0",
        "notes": "Comprehensive study of clinical trial costs by phase and therapeutic area"
      },
      "DiMasi_2016": {
        "title": "Innovation in the pharmaceutical industry: New estimates of R&D costs",
        "authors": "DiMasi JA, Grabowski HG, Hansen RW",
        "journal": "Journal of Health Economics",
        "year": 2016,
        "url": "https://doi.org/10.1016/j.jhealeco.2016.01.012",
        "notes": "Landmark study estimating $2.6B total development cost per approved drug"
      },
      "Sertkaya_2016": {
        "title": "Key cost drivers of pharmaceutical clinical trials in the United States",
        "authors": "Sertkaya A, Wong HH, Jessup A, Beleche T",
        "journal": "Clinical Trials",
        "year": 2016,
        "url": "https://doi.org/10.1177/1740774516677887",
        "notes": "ASPE-commissioned study on clinical trial cost drivers"
      }
    }
  },

  "phase_transition_probabilities": {
    "_description": "Success rates for transitioning between clinical development phases",
    "_source_primary": "BIO_QLS_2021",
    "_notes": "Values from BIO/QLS/Informa 2011-2020 analysis of 12,728 phase transitions. Phase II remains the largest hurdle with just 28.9% success.",

    "overall_all_indications": {
      "source": "BIO_QLS_2021",
      "period": "2011-2020",
      "sample_size": 12728,
      "phase_1_to_2": 0.520,
      "phase_2_to_3": 0.289,
      "phase_3_to_approval": 0.578,
      "nda_bla_to_approval": 0.906,
      "overall_loa_from_phase_1": 0.079,
      "overall_loa_from_phase_2": 0.151,
      "overall_loa_from_phase_3": 0.524,
      "notes": "Overall LOA of 7.9% from Phase I. Average 10.5 years from Phase I to approval."
    },

    "by_therapeutic_area": {
      "_notes": "All data from BIO_QLS_2021 Figure 2 and Figure 5. Ordered by LOA from Phase I (highest to lowest).",

      "hematology": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 92, "phase_2": 106, "phase_3": 82, "nda_bla": 72},
        "phase_1_to_2": 0.696,
        "phase_2_to_3": 0.481,
        "phase_3_to_approval": 0.768,
        "nda_bla_to_approval": 0.931,
        "overall_loa_from_phase_1": 0.239,
        "overall_loa_from_phase_2": 0.344,
        "overall_loa_from_phase_3": 0.715,
        "notes": "Highest LOA (23.9%). Dominated by hemophilia research with extremely well-characterized biology."
      },

      "metabolic": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 136, "phase_2": 149, "phase_3": 66, "nda_bla": 48},
        "phase_1_to_2": 0.618,
        "phase_2_to_3": 0.450,
        "phase_3_to_approval": 0.636,
        "nda_bla_to_approval": 0.875,
        "overall_loa_from_phase_1": 0.155,
        "overall_loa_from_phase_2": 0.250,
        "overall_loa_from_phase_3": 0.557
      },

      "infectious_disease": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 403, "phase_2": 414, "phase_3": 197, "nda_bla": 156},
        "phase_1_to_2": 0.578,
        "phase_2_to_3": 0.384,
        "phase_3_to_approval": 0.640,
        "nda_bla_to_approval": 0.929,
        "overall_loa_from_phase_1": 0.132,
        "overall_loa_from_phase_2": 0.228,
        "overall_loa_from_phase_3": 0.594
      },

      "ophthalmology": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 88, "phase_2": 200, "phase_3": 82, "nda_bla": 45},
        "phase_1_to_2": 0.716,
        "phase_2_to_3": 0.355,
        "phase_3_to_approval": 0.512,
        "nda_bla_to_approval": 0.911,
        "overall_loa_from_phase_1": 0.119,
        "overall_loa_from_phase_2": 0.166,
        "overall_loa_from_phase_3": 0.467
      },

      "autoimmune_inflammation": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 413, "phase_2": 471, "phase_3": 219, "nda_bla": 202},
        "phase_1_to_2": 0.552,
        "phase_2_to_3": 0.314,
        "phase_3_to_approval": 0.653,
        "nda_bla_to_approval": 0.941,
        "overall_loa_from_phase_1": 0.107,
        "overall_loa_from_phase_2": 0.193,
        "overall_loa_from_phase_3": 0.614
      },

      "allergy": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 55, "phase_2": 92, "phase_3": 34, "nda_bla": 20},
        "phase_1_to_2": 0.564,
        "phase_2_to_3": 0.283,
        "phase_3_to_approval": 0.647,
        "nda_bla_to_approval": 1.000,
        "overall_loa_from_phase_1": 0.103,
        "overall_loa_from_phase_2": 0.183,
        "overall_loa_from_phase_3": 0.647
      },

      "gastroenterology": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 45, "phase_2": 73, "phase_3": 35, "nda_bla": 33},
        "phase_1_to_2": 0.467,
        "phase_2_to_3": 0.342,
        "phase_3_to_approval": 0.571,
        "nda_bla_to_approval": 0.909,
        "overall_loa_from_phase_1": 0.083,
        "overall_loa_from_phase_2": 0.178,
        "overall_loa_from_phase_3": 0.519,
        "notes": "Excludes IBD which is classified under autoimmune"
      },

      "respiratory": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 179, "phase_2": 215, "phase_3": 62, "nda_bla": 45},
        "phase_1_to_2": 0.559,
        "phase_2_to_3": 0.219,
        "phase_3_to_approval": 0.645,
        "nda_bla_to_approval": 0.956,
        "overall_loa_from_phase_1": 0.075,
        "overall_loa_from_phase_2": 0.135,
        "overall_loa_from_phase_3": 0.616
      },

      "psychiatry": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 150, "phase_2": 164, "phase_3": 71, "nda_bla": 57},
        "phase_1_to_2": 0.527,
        "phase_2_to_3": 0.268,
        "phase_3_to_approval": 0.563,
        "nda_bla_to_approval": 0.912,
        "overall_loa_from_phase_1": 0.073,
        "overall_loa_from_phase_2": 0.138,
        "overall_loa_from_phase_3": 0.514
      },

      "endocrine": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 319, "phase_2": 293, "phase_3": 151, "nda_bla": 124},
        "phase_1_to_2": 0.433,
        "phase_2_to_3": 0.266,
        "phase_3_to_approval": 0.662,
        "nda_bla_to_approval": 0.863,
        "overall_loa_from_phase_1": 0.066,
        "overall_loa_from_phase_2": 0.152,
        "overall_loa_from_phase_3": 0.571
      },

      "neurology": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 516, "phase_2": 504, "phase_3": 226, "nda_bla": 165},
        "phase_1_to_2": 0.477,
        "phase_2_to_3": 0.268,
        "phase_3_to_approval": 0.531,
        "nda_bla_to_approval": 0.867,
        "overall_loa_from_phase_1": 0.059,
        "overall_loa_from_phase_2": 0.123,
        "overall_loa_from_phase_3": 0.460,
        "notes": "Phase II rate close to average, but Phase III and NDA/BLA underperform. Neurodegenerative diseases often progress to late-stage on biomarker data without clinical PoC."
      },

      "oncology": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 1628, "phase_2": 1732, "phase_3": 495, "nda_bla": 324},
        "phase_1_to_2": 0.488,
        "phase_2_to_3": 0.246,
        "phase_3_to_approval": 0.477,
        "nda_bla_to_approval": 0.920,
        "overall_loa_from_phase_1": 0.053,
        "overall_loa_from_phase_2": 0.108,
        "overall_loa_from_phase_3": 0.439,
        "notes": "Largest segment (33% of all transitions) with third-lowest LOA. Marginally improved from 5.1% in 2006-2015."
      },

      "cardiovascular": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 214, "phase_2": 252, "phase_3": 105, "nda_bla": 80},
        "phase_1_to_2": 0.500,
        "phase_2_to_3": 0.210,
        "phase_3_to_approval": 0.552,
        "nda_bla_to_approval": 0.825,
        "overall_loa_from_phase_1": 0.048,
        "overall_loa_from_phase_2": 0.096,
        "overall_loa_from_phase_3": 0.456,
        "notes": "Low biologic penetration (1:3 ratio vs 1:1 in autoimmune). Large outcome trials drive long Phase III durations."
      },

      "urology": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 22, "phase_2": 40, "phase_3": 13, "nda_bla": 13},
        "phase_1_to_2": 0.409,
        "phase_2_to_3": 0.150,
        "phase_3_to_approval": 0.692,
        "nda_bla_to_approval": 0.846,
        "overall_loa_from_phase_1": 0.036,
        "overall_loa_from_phase_2": 0.088,
        "overall_loa_from_phase_3": 0.586,
        "notes": "Lowest LOA (3.6%). Small sample size. Lowest Phase II success rate (15%)."
      }
    },

    "oncology_subcategories": {
      "_notes": "Oncology broken down by tumor type and treatment approach. From BIO_QLS_2021 Figure 7.",

      "non_oncology": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 2786, "phase_2": 3201, "phase_3": 1433, "nda_bla": 1129},
        "phase_1_to_2": 0.539,
        "phase_2_to_3": 0.312,
        "phase_3_to_approval": 0.613,
        "nda_bla_to_approval": 0.902,
        "overall_loa_from_phase_1": 0.093,
        "overall_loa_from_phase_2": 0.172,
        "overall_loa_from_phase_3": 0.553
      },

      "oncology_all": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 1628, "phase_2": 1732, "phase_3": 495, "nda_bla": 324},
        "phase_1_to_2": 0.488,
        "phase_2_to_3": 0.246,
        "phase_3_to_approval": 0.477,
        "nda_bla_to_approval": 0.920,
        "overall_loa_from_phase_1": 0.053,
        "overall_loa_from_phase_2": 0.108,
        "overall_loa_from_phase_3": 0.439
      },

      "hematologic_cancers": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 425, "phase_2": 449, "phase_3": 120, "nda_bla": 100},
        "phase_1_to_2": 0.501,
        "phase_2_to_3": 0.278,
        "phase_3_to_approval": 0.600,
        "nda_bla_to_approval": 0.900,
        "overall_loa_from_phase_1": 0.075,
        "overall_loa_from_phase_2": 0.150,
        "overall_loa_from_phase_3": 0.540,
        "notes": "Blood cancers. Higher success than solid tumors. Typically classified as rare diseases."
      },

      "solid_tumors": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 1145, "phase_2": 1261, "phase_3": 364, "nda_bla": 212},
        "phase_1_to_2": 0.489,
        "phase_2_to_3": 0.234,
        "phase_3_to_approval": 0.429,
        "nda_bla_to_approval": 0.929,
        "overall_loa_from_phase_1": 0.046,
        "overall_loa_from_phase_2": 0.093,
        "overall_loa_from_phase_3": 0.398,
        "notes": "Over 2x the transitions of hematologic but much lower LOA (4.6% vs 7.5%)."
      },

      "immuno_oncology": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 275, "phase_2": 244, "phase_3": 98, "nda_bla": 62},
        "phase_1_to_2": 0.640,
        "phase_2_to_3": 0.402,
        "phase_3_to_approval": 0.490,
        "nda_bla_to_approval": 0.984,
        "overall_loa_from_phase_1": 0.124,
        "overall_loa_from_phase_2": 0.194,
        "overall_loa_from_phase_3": 0.482,
        "notes": "IO drugs significantly outperform traditional oncology (12.4% vs 5.3% LOA). Phase II rate of 40.2% vs 24.6% overall oncology is key driver."
      }
    },

    "rare_vs_chronic_disease": {
      "_notes": "Comparison of rare diseases vs chronic high prevalence diseases. From BIO_QLS_2021 Figure 8. Oncology excluded from both groups.",

      "rare_diseases_non_oncology": {
        "source": "BIO_QLS_2021",
        "definition": "Affects <200,000 patients in US or prevalence <1:2,000 in EU. Oncology excluded.",
        "sample_sizes": {"phase_1": 380, "phase_2": 464, "phase_3": 240, "nda_bla": 172},
        "phase_1_to_2": 0.674,
        "phase_2_to_3": 0.446,
        "phase_3_to_approval": 0.604,
        "nda_bla_to_approval": 0.936,
        "overall_loa_from_phase_1": 0.170,
        "overall_loa_from_phase_2": 0.252,
        "overall_loa_from_phase_3": 0.566,
        "notes": "Nearly 3x the LOA of chronic diseases (17.0% vs 5.9%). 1,256 total transitions from 685 developers."
      },

      "chronic_high_prevalence": {
        "source": "BIO_QLS_2021",
        "definition": ">1 million patients affected in US. From CMS Chronic Conditions Data Warehouse list, excluding cancer.",
        "sample_sizes": {"phase_1": 745, "phase_2": 737, "phase_3": 279, "nda_bla": 217},
        "phase_1_to_2": 0.460,
        "phase_2_to_3": 0.231,
        "phase_3_to_approval": 0.595,
        "nda_bla_to_approval": 0.926,
        "overall_loa_from_phase_1": 0.059,
        "overall_loa_from_phase_2": 0.127,
        "overall_loa_from_phase_3": 0.551,
        "notes": "16% of total transitions. Together with oncology (33%), these two groups comprise half the dataset with below-average LOAs."
      },

      "rare_diseases_oncology": {
        "source": "BIO_QLS_2021",
        "overall_loa_from_phase_1": 0.068,
        "notes": "Rare oncology indications (43% of oncology) have higher LOA than non-rare oncology (6.8% vs 4.4%), driven by hematologic malignancies."
      }
    },

    "by_drug_class_and_modality": {
      "_notes": "Success rates by drug novelty and modality. From BIO_QLS_2021 Figures 9 and 10.",

      "novel_drugs": {
        "source": "BIO_QLS_2021",
        "includes": ["NME", "biologic", "vaccine"],
        "sample_sizes": {"phase_1": 3933, "phase_2": 4394, "phase_3": 1374, "nda_bla": 826},
        "phase_1_to_2": 0.513,
        "phase_2_to_3": 0.279,
        "phase_3_to_approval": 0.529,
        "nda_bla_to_approval": 0.896,
        "overall_loa_from_phase_1": 0.068,
        "overall_loa_from_phase_2": 0.132,
        "overall_loa_from_phase_3": 0.474
      },

      "nme_small_molecules": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 2505, "phase_2": 2924, "phase_3": 869, "nda_bla": 505},
        "phase_1_to_2": 0.506,
        "phase_2_to_3": 0.256,
        "phase_3_to_approval": 0.506,
        "nda_bla_to_approval": 0.861,
        "overall_loa_from_phase_1": 0.057,
        "overall_loa_from_phase_2": 0.112,
        "overall_loa_from_phase_3": 0.436
      },

      "biologics": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 1301, "phase_2": 1355, "phase_3": 462, "nda_bla": 294},
        "phase_1_to_2": 0.525,
        "phase_2_to_3": 0.324,
        "phase_3_to_approval": 0.567,
        "nda_bla_to_approval": 0.946,
        "overall_loa_from_phase_1": 0.091,
        "overall_loa_from_phase_2": 0.174,
        "overall_loa_from_phase_3": 0.536
      },

      "vaccines": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 127, "phase_2": 115, "phase_3": 43, "nda_bla": 27},
        "phase_1_to_2": 0.520,
        "phase_2_to_3": 0.322,
        "phase_3_to_approval": 0.581,
        "nda_bla_to_approval": 1.000,
        "overall_loa_from_phase_1": 0.097,
        "overall_loa_from_phase_2": 0.187,
        "overall_loa_from_phase_3": 0.581
      },

      "off_patent": {
        "source": "BIO_QLS_2021",
        "includes": ["non-NME", "biosimilar"],
        "sample_sizes": {"phase_1": 455, "phase_2": 527, "phase_3": 552, "nda_bla": 627},
        "phase_1_to_2": 0.604,
        "phase_2_to_3": 0.376,
        "phase_3_to_approval": 0.703,
        "nda_bla_to_approval": 0.919,
        "overall_loa_from_phase_1": 0.147,
        "overall_loa_from_phase_2": 0.243,
        "overall_loa_from_phase_3": 0.646,
        "notes": "2x the LOA of novel drugs (14.7% vs 6.8%). Relies on established science."
      },

      "non_nme": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 395, "phase_2": 523, "phase_3": 471, "nda_bla": 495},
        "phase_1_to_2": 0.575,
        "phase_2_to_3": 0.375,
        "phase_3_to_approval": 0.675,
        "nda_bla_to_approval": 0.915,
        "overall_loa_from_phase_1": 0.133,
        "overall_loa_from_phase_2": 0.232,
        "overall_loa_from_phase_3": 0.618
      },

      "biosimilars": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 60, "phase_2": 4, "phase_3": 81, "nda_bla": 132},
        "phase_1_to_2": 0.800,
        "phase_2_to_3": 0.500,
        "phase_3_to_approval": 0.864,
        "nda_bla_to_approval": 0.932,
        "overall_loa_from_phase_1": 0.322,
        "overall_loa_from_phase_2": 0.403,
        "overall_loa_from_phase_3": 0.805,
        "notes": "Highest LOA (32.2%). Small Phase II sample due to abbreviated pathways."
      }
    },

    "by_modality_detailed": {
      "_notes": "Detailed modality breakdown. From BIO_QLS_2021 Figure 10. Ordered by LOA from Phase I.",

      "car_t": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 43, "phase_2": 17, "phase_3": 3, "nda_bla": 4},
        "phase_1_to_2": 0.442,
        "phase_2_to_3": 0.588,
        "phase_3_to_approval": 0.667,
        "nda_bla_to_approval": 1.000,
        "overall_loa_from_phase_1": 0.173,
        "overall_loa_from_phase_2": 0.392,
        "overall_loa_from_phase_3": 0.667,
        "notes": "Highest LOA among modalities (17.3%). 3 separate CAR-Ts approved since 2017."
      },

      "sirna_rnai": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 40, "phase_2": 38, "phase_3": 6, "nda_bla": 3},
        "phase_1_to_2": 0.700,
        "phase_2_to_3": 0.289,
        "phase_3_to_approval": 0.667,
        "nda_bla_to_approval": 1.000,
        "overall_loa_from_phase_1": 0.135,
        "overall_loa_from_phase_2": 0.193,
        "overall_loa_from_phase_3": 0.667,
        "notes": "Second highest LOA (13.5%). 3 approvals as of Dec 2020, first in 2018."
      },

      "monoclonal_antibody": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 804, "phase_2": 740, "phase_3": 310, "nda_bla": 282},
        "phase_1_to_2": 0.547,
        "phase_2_to_3": 0.341,
        "phase_3_to_approval": 0.681,
        "nda_bla_to_approval": 0.954,
        "overall_loa_from_phase_1": 0.121,
        "overall_loa_from_phase_2": 0.221,
        "overall_loa_from_phase_3": 0.649,
        "notes": "Mature modality with considerably improved LOA vs older drug classes."
      },

      "adcs": {
        "source": "BIO_QLS_2021",
        "definition": "Antibody-drug conjugates",
        "sample_sizes": {"phase_1": 103, "phase_2": 53, "phase_3": 16, "nda_bla": 12},
        "phase_1_to_2": 0.417,
        "phase_2_to_3": 0.415,
        "phase_3_to_approval": 0.625,
        "nda_bla_to_approval": 1.000,
        "overall_loa_from_phase_1": 0.108,
        "overall_loa_from_phase_2": 0.259,
        "overall_loa_from_phase_3": 0.625
      },

      "gene_therapy": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 27, "phase_2": 57, "phase_3": 10, "nda_bla": 2},
        "phase_1_to_2": 0.519,
        "phase_2_to_3": 0.386,
        "phase_3_to_approval": 0.500,
        "nda_bla_to_approval": 1.000,
        "overall_loa_from_phase_1": 0.100,
        "overall_loa_from_phase_2": 0.193,
        "overall_loa_from_phase_3": 0.500
      },

      "protein": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 246, "phase_2": 288, "phase_3": 149, "nda_bla": 117},
        "phase_1_to_2": 0.516,
        "phase_2_to_3": 0.330,
        "phase_3_to_approval": 0.617,
        "nda_bla_to_approval": 0.897,
        "overall_loa_from_phase_1": 0.094,
        "overall_loa_from_phase_2": 0.183,
        "overall_loa_from_phase_3": 0.554
      },

      "peptide": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 234, "phase_2": 218, "phase_3": 100, "nda_bla": 67},
        "phase_1_to_2": 0.530,
        "phase_2_to_3": 0.284,
        "phase_3_to_approval": 0.600,
        "nda_bla_to_approval": 0.881,
        "overall_loa_from_phase_1": 0.080,
        "overall_loa_from_phase_2": 0.150,
        "overall_loa_from_phase_3": 0.528
      },

      "small_molecule": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 2308, "phase_2": 2896, "phase_3": 1118, "nda_bla": 849},
        "phase_1_to_2": 0.526,
        "phase_2_to_3": 0.280,
        "phase_3_to_approval": 0.569,
        "nda_bla_to_approval": 0.895,
        "overall_loa_from_phase_1": 0.075,
        "overall_loa_from_phase_2": 0.143,
        "overall_loa_from_phase_3": 0.509,
        "notes": "57% of all transitions. Modest LOA despite dominance."
      },

      "antisense": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 69, "phase_2": 70, "phase_3": 14, "nda_bla": 9},
        "phase_1_to_2": 0.609,
        "phase_2_to_3": 0.200,
        "phase_3_to_approval": 0.643,
        "nda_bla_to_approval": 0.667,
        "overall_loa_from_phase_1": 0.052,
        "overall_loa_from_phase_2": 0.086,
        "overall_loa_from_phase_3": 0.429,
        "notes": "Lowest LOA among modalities (5.2%). Low NDA/BLA approval rate (66.7%)."
      }
    },

    "biomarker_impact": {
      "_notes": "Impact of patient preselection biomarkers. From BIO_QLS_2021 Figure 11. 767 transitions (6%) incorporated biomarkers.",

      "with_preselection_biomarkers": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 414, "phase_2": 149, "phase_3": 129, "nda_bla": 75},
        "phase_1_to_2": 0.524,
        "phase_2_to_3": 0.463,
        "phase_3_to_approval": 0.682,
        "nda_bla_to_approval": 0.960,
        "overall_loa_from_phase_1": 0.159,
        "overall_loa_from_phase_2": 0.303,
        "overall_loa_from_phase_3": 0.655,
        "notes": "2x the LOA of programs without biomarkers (15.9% vs 7.6%)."
      },

      "without_biomarkers": {
        "source": "BIO_QLS_2021",
        "sample_sizes": {"phase_1": 4000, "phase_2": 4784, "phase_3": 1799, "nda_bla": 1378},
        "phase_1_to_2": 0.520,
        "phase_2_to_3": 0.283,
        "phase_3_to_approval": 0.571,
        "nda_bla_to_approval": 0.903,
        "overall_loa_from_phase_1": 0.076,
        "overall_loa_from_phase_2": 0.146,
        "overall_loa_from_phase_3": 0.515
      },

      "phase_specific_impact": {
        "source": "BIO_QLS_2021",
        "notes": "Biomarker benefit varies by phase: no discernible difference at Phase I (52.4% vs 52.0%). Greatest benefit at Phase II (46.3% vs 28.3%). Smaller but significant benefit at Phase III (68.2% vs 57.1%)."
      },

      "phase_specific_multipliers_wong": {
        "source": "Wong_2019",
        "notes": "Original Wong et al. phase-specific multipliers based on 2000-2015 data. Use for adjustments when BIO data unavailable.",
        "phase_1_to_2": 1.28,
        "phase_2_to_3": 1.44,
        "phase_3_to_approval": 1.02,
        "overall_loa_multiplier": 1.87,
        "application_method": "Apply multipliers to baseline therapeutic area rates. For validated biomarkers (e.g., HER2+, EGFR+, PD-L1+), use full multipliers. For exploratory biomarkers, use 50-75% of effect.",
        "data_limitation": "Based on oncology data only. Generalizability to other therapeutic areas is uncertain."
      }
    }
  },

  "development_timelines": {
    "_description": "Drug development timelines by phase and therapeutic area",
    "_source_primary": "BIO_QLS_2021",
    "_notes": "Based on 6,151 successful phase transitions from 2011-2020.",

    "overall_average": {
      "source": "BIO_QLS_2021",
      "total_years_phase_1_to_approval": 10.5,
      "phase_1_duration_years": 2.3,
      "phase_2_duration_years": 3.6,
      "phase_3_duration_years": 3.3,
      "regulatory_duration_years": 1.3,
      "notes": "Longer timelines correlate with lower LOA. Disease areas with above-average LOA tend to have shorter development times."
    },

    "by_therapeutic_area": {
      "_notes": "From BIO_QLS_2021 Figure 17. Ordered by total duration (shortest to longest).",

      "allergy": {
        "phase_1_years": 1.5, "phase_2_years": 3.8, "phase_3_years": 2.9, "regulatory_years": 1.1,
        "total_years": 9.2
      },
      "metabolic": {
        "phase_1_years": 2.0, "phase_2_years": 3.2, "phase_3_years": 3.1, "regulatory_years": 1.2,
        "total_years": 9.5
      },
      "infectious_disease": {
        "phase_1_years": 2.0, "phase_2_years": 3.5, "phase_3_years": 3.1, "regulatory_years": 1.2,
        "total_years": 9.7
      },
      "ophthalmology": {
        "phase_1_years": 2.1, "phase_2_years": 2.9, "phase_3_years": 3.4, "regulatory_years": 1.3,
        "total_years": 9.8
      },
      "autoimmune": {
        "phase_1_years": 2.1, "phase_2_years": 3.6, "phase_3_years": 3.2, "regulatory_years": 1.1,
        "total_years": 10.0
      },
      "oncology": {
        "phase_1_years": 2.7, "phase_2_years": 3.7, "phase_3_years": 3.1, "regulatory_years": 0.8,
        "total_years": 10.3,
        "notes": "Longest Phase I (2.7 years) due to basket trial designs. Shortest regulatory (0.8 years) due to expedited pathways and RTOR."
      },
      "respiratory": {
        "phase_1_years": 2.1, "phase_2_years": 3.5, "phase_3_years": 3.3, "regulatory_years": 1.5,
        "total_years": 10.4
      },
      "psychiatry": {
        "phase_1_years": 2.3, "phase_2_years": 3.4, "phase_3_years": 2.8, "regulatory_years": 1.8,
        "total_years": 10.4
      },
      "endocrine": {
        "phase_1_years": 1.8, "phase_2_years": 3.4, "phase_3_years": 3.7, "regulatory_years": 1.8,
        "total_years": 10.7
      },
      "hematology": {
        "phase_1_years": 2.2, "phase_2_years": 3.4, "phase_3_years": 3.6, "regulatory_years": 1.5,
        "total_years": 10.7
      },
      "gastroenterology": {
        "phase_1_years": 1.6, "phase_2_years": 3.9, "phase_3_years": 3.9, "regulatory_years": 1.4,
        "total_years": 10.8
      },
      "neurology": {
        "phase_1_years": 2.1, "phase_2_years": 3.7, "phase_3_years": 3.7, "regulatory_years": 1.6,
        "total_years": 11.1
      },
      "cardiovascular": {
        "phase_1_years": 2.4, "phase_2_years": 3.8, "phase_3_years": 4.2, "regulatory_years": 1.2,
        "total_years": 11.5,
        "notes": "Longest Phase III (4.2 years) due to large outcome studies and long-term endpoint evaluation."
      },
      "urology": {
        "phase_1_years": 2.7, "phase_2_years": 5.0, "phase_3_years": 2.9, "regulatory_years": 1.6,
        "total_years": 12.2,
        "notes": "Longest overall duration (12.2 years). Longest Phase II (5.0 years, n=6)."
      }
    }
  },

  "clinical_trial_costs": {
    "_description": "Clinical trial costs by phase and therapeutic area in USD millions (unless otherwise noted)",
    "_source_primary": "ASPE_2014, DiMasi_2016",
    "_notes": "Costs vary significantly based on trial design, geography, patient population, and endpoints. ASPE 2014 costs should be inflation-adjusted (~89% increase to 2026 dollars using 5% annual inflation).",

    "average_costs_by_phase": {
      "source": "ASPE_2014",
      "base_year": 2014,
      "inflation_factor_to_2026": 1.89,
      "phase_1": {
        "cost_2014_millions": 3.8,
        "cost_2026_millions": 7.2,
        "range_2026_millions": [2, 10],
        "average_patients": 39
      },
      "phase_2": {
        "cost_2014_millions": 13.35,
        "cost_2026_millions": 25.2,
        "range_2026_millions": [13, 40],
        "average_patients": 143
      },
      "phase_3": {
        "cost_2014_millions": 19.89,
        "cost_2026_millions": 37.6,
        "range_2026_millions": [40, 200],
        "average_patients": 479,
        "notes": "ASPE average underestimates large pivotal trials. Oncology Phase III often exceeds $50M."
      },
      "regulatory_approval": {
        "cost_millions": 2.5,
        "range_millions": [1, 5]
      }
    },

    "per_patient_costs_by_therapeutic_area": {
      "source": "Industry estimates 2024",
      "_units": "USD per patient",
      "oncology": {
        "phase_1": 152000,
        "phase_2": 130500,
        "phase_3": 124800,
        "notes": "Highest cost therapeutic area. Complex protocols, specialized monitoring."
      },
      "neurology": {
        "phase_1": 158000,
        "phase_2": 139200,
        "phase_3": 122105,
        "notes": "Long trial durations, complex endpoints, imaging requirements."
      },
      "cardiovascular": {
        "phase_1": 135000,
        "phase_2": 127000,
        "phase_3": 121000
      },
      "psychiatry": {
        "phase_1": 139000,
        "phase_2": 125700,
        "phase_3": 118000
      },
      "respiratory": {
        "phase_1": 127800,
        "phase_2": 121200,
        "phase_3": 116940
      },
      "infectious_disease": {
        "phase_1": 122000,
        "phase_2": 119500,
        "phase_3": 111100
      },
      "dermatology": {
        "phase_1": 110000,
        "phase_2": 104000,
        "phase_3": 99800,
        "notes": "Lowest cost therapeutic area."
      }
    },

    "by_modality_cost_multipliers": {
      "source": "Industry estimates",
      "small_molecule": 1.0,
      "biologic": 1.5,
      "cell_therapy": 3.0,
      "gene_therapy": 4.0,
      "notes": "Multipliers relative to small molecule baseline. Cell/gene therapy costs driven by manufacturing complexity."
    }
  },

  "indication_specific_data": {
    "_description": "Detailed data for specific high-value indications",

    "alzheimers_disease": {
      "therapeutic_area": "neurology",
      "phase_transition_probabilities": {
        "source": "BIO_QLS_2021, industry analyses",
        "phase_1_to_2": 0.65,
        "phase_2_to_3": 0.25,
        "phase_3_to_approval": 0.30,
        "overall_loa_from_phase_1": 0.05,
        "notes": "Among lowest success rates. Long trial durations, complex endpoints, high placebo response."
      }
    },

    "breast_cancer": {
      "therapeutic_area": "oncology",
      "phase_transition_probabilities": {
        "source": "BIO_QLS_2021",
        "phase_1_to_2": 0.60,
        "phase_2_to_3": 0.40,
        "phase_3_to_approval": 0.50,
        "overall_loa_from_phase_1": 0.10,
        "notes": "Above average for oncology due to well-defined biomarkers (HER2, HR status)"
      }
    },

    "non_small_cell_lung_cancer": {
      "therapeutic_area": "oncology",
      "phase_transition_probabilities": {
        "source": "BIO_QLS_2021",
        "phase_1_to_2": 0.55,
        "phase_2_to_3": 0.35,
        "phase_3_to_approval": 0.45,
        "overall_loa_from_phase_1": 0.07,
        "notes": "Improved with targeted therapies (EGFR, ALK) and immunotherapy"
      }
    },

    "pancreatic_cancer": {
      "therapeutic_area": "oncology",
      "phase_transition_probabilities": {
        "source": "BIO_QLS_2021",
        "overall_loa_from_phase_1": 0.011,
        "notes": "Minimum LOA in oncology (1.1%, n=275). Extremely challenging indication."
      }
    },

    "alimentary_cancers": {
      "therapeutic_area": "oncology",
      "phase_transition_probabilities": {
        "source": "BIO_QLS_2021",
        "overall_loa_from_phase_1": 0.152,
        "notes": "Maximum LOA in oncology (15.2%, n=33). Small sample size."
      }
    },

    "pd1_pdl1_immunotherapy": {
      "therapeutic_area": "oncology",
      "phase_transition_probabilities": {
        "source": "BIO_QLS_2021 (Part 2)",
        "overall_loa_from_phase_1": 0.239,
        "notes": "PD-1/PD-L1 immunotherapies tremendously successful from Phase I (23.9%, n=71). Other immunotherapies much less successful (1.9%, n=945)."
      }
    },

    "hemophilia_a": {
      "therapeutic_area": "hematology",
      "phase_transition_probabilities": {
        "source": "BIO_QLS_2021",
        "phase_2_to_3": 1.00,
        "overall_success": "32 of 34 phase transitions successful",
        "notes": "Extremely well-characterized biology. 100% Phase II success rate (n=6)."
      }
    }
  },

  "adjustments_and_factors": {
    "_description": "Factors that can adjust baseline probabilities",

    "breakthrough_therapy_designation": {
      "source": "BIO_QLS_2021 (Part 2)",
      "approval_probability_increase": 0.206,
      "notes": "Top positive feature in ML analysis. +20.6% contribution to POA above baseline."
    },

    "orphan_drug_designation": {
      "approval_rate_multiplier": 1.3,
      "notes": "Smaller trial sizes, expedited pathways, higher success"
    },

    "prior_approval_other_indication": {
      "source": "BIO_QLS_2021 (Part 2)",
      "approval_probability_increase": 0.036,
      "notes": "+3.6% contribution. Controlled manufacturing, established safety profile."
    },

    "first_in_class": {
      "success_rate_multiplier": 0.8,
      "notes": "Higher risk due to novel mechanism"
    },

    "validated_target": {
      "success_rate_multiplier": 1.3,
      "notes": "Target previously validated by approved drug"
    },

    "sponsor_track_record": {
      "source": "BIO_QLS_2021 (Part 2)",
      "notes": "Positive correlation between sponsor's prior successful phase transitions and future success. Associated with operational experience in trials and regulatory navigation."
    }
  },

  "ml_predictive_factors": {
    "_description": "Top features predicting clinical success from QLS machine learning analysis",
    "_source": "BIO_QLS_2021 Part 2",
    "_notes": "Ranked by feature importance across 200+ variables analyzed",

    "top_predictive_factors": [
      {"rank": 1, "factor": "Indication", "notes": "Consistently ranked top variable across all phases. Success varies substantially within therapeutic areas."},
      {"rank": 2, "factor": "Biological target", "notes": "Target validation status significantly impacts success."},
      {"rank": 3, "factor": "Drug modality", "notes": "mAbs 5.9% LOA in oncology vs other modalities."},
      {"rank": 4, "factor": "Lead indication status", "notes": "Lead indications may have higher success if follow-on indications fail."},
      {"rank": 5, "factor": "Prior approval for another indication", "notes": "Established manufacturing and safety profile."},
      {"rank": 6, "factor": "Sponsor has prior success in therapeutic area", "notes": "Track record correlates with future success."},
      {"rank": 7, "factor": "Trial outcome (primary endpoints met)", "notes": "Significant association with late-stage success."},
      {"rank": 8, "factor": "Fast track designation", "notes": "FDA expedited pathway."},
      {"rank": 9, "factor": "Breakthrough therapy designation", "notes": "+20.6% contribution to POA."},
      {"rank": 10, "factor": "Orphan drug designation", "notes": "Regulatory incentives and smaller trials."},
      {"rank": 11, "factor": "Patient preselection biomarkers", "notes": "2x LOA improvement, especially at Phase II."}
    ]
  }
}
